Japan-based study underway for Caladrius Bio's CD34 cell therapy in critical limb ischemia

|About: Caladrius Biosciences,... (CLBS)|By:, SA News Editor

The first patient has been dosed in a Phase 2 clinical trial in Japan evaluating Caladrius Biosciences' (NASDAQ:CLBS) CLBS12, a CD34 cell therapy, in patients with no-option critical limb ischemia (CLI) (severely restricted blood flow to the extremities).

The 35-subject study will compare CLBS12 + standard-of-care (SOC) drug therapy to SOC drug therapy alone. The primary endpoint is the time to continuous CLI-free status.

If successful, the company plans to apply for conditional approval there for the indication.

Subscribe for full text news in your inbox